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Abstract:  
Background: 
Current consensus statements maintain that endoscopic vein harvesting (EVH) should be standard care in 
coronary artery bypass surgery (CABG) but vein quality and clinical outcomes have been questioned. The Vein 
Integrity and Clinical Outcome (VICO) trial was designed to assess the impact of different vein harvesting 
methods on vessel damage and if this contributes to clinical outcomes following CABG.  
Methods: 
A single centre, randomised clinical trial of patients undergoing CABG with an internal mammary artery, and with 
one to four vein grafts were recruited. All the veins were harvested by a single experienced practitioner. We 
randomly allocated n=300 patients into: closed tunnel CO2 EVH (CT-EVH) (n=100), open tunnel CO2 EVH (OT-
EVH) (n=100) and traditional open vein harvesting (OVH) (n=100) groups. The primary end-point was endothelial 
integrity and muscular damages of the harvested vein. Secondary end-points included clinical outcomes (major 
adverse cardiac events, MACE), use of healthcare resources and impact on health status (quality-adjusted life 
years, QALYs).  
Results: 
The OVH group demonstrated marginally better endothelial integrity in random samples (85% vs. 88% vs. 93% 
for CT-EVH, OT-EVH and OVH, p<0.001). CT-EVH displayed the lowest longitudinal hypertrophy (1% vs. 13.5% 
vs. 3%, p=0.001). However, no differences in endothelial stretching were observed between groups (37% vs. 
37% vs. 31%, p=0.62). Secondary clinical outcomes demonstrated no significant differences in composite MACE 
scores at each time point up to 48 months. The QALY gain per patient was: 0.11 (p<0.001) for closed tunnel CO2 
EVH and 0.07 (p=0.003) for open tunnel CO2 EVH compared with open vein harvesting. The likelihood of being 
cost-effective, at a pre-defined threshold of £20,000 per QALY gained was: 75% for closed tunnel, 19% for open 
tunnel and 6% for open vein harvesting.  
Conclusion: 
Our study demonstrates that harvesting techniques do impact upon integrity of different vein layers, albeit with 
only a small effect. Secondary outcomes suggest that histological findings do not directly contribute to MACE 
outcomes. Gains in health status were observed and cost-effectiveness was better with CT-EVH. High level 
experience with endoscopic harvesting performed by a dedicated specialist practitioner gives optimal results 
which is comparable to open vein harvesting. 
 
Clinical Trial Registration: 
ISRCTN: 91485426.    URL: https://www.isrctn.com.   
       
Keywords: Coronary artery bypass surgery, open vein harvesting, closed tunnel endoscopic vein harvesting,  
                   open tunnel endoscopic vein harvesting, endothelial integrity, clinical outcomes, cost effectiveness. 
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Clinical perspective: 
What is new? 
- The VICO trial is the first study to directly evaluate the impact of minimally invasive 
and open vein harvesting techniques on the collective outcomes of endothelial 
integrity of the graft, clinical outcomes, health-related quality of life and cost 
effectiveness.  
- The study aimed to determine if vein damage during harvesting contributed to 
outcomes following surgery. A single centre, sole operator study was selected to 
minimise the incidence of practitioner skill error as this could markedly impair the 
validity of any findings between endoscopic vein harvesting methods.  
What are the clinical implications?  
- This study demonstrates that endoscopic vein harvesting induces minimal damage to 
vessel integrity yet there is no direct correlation with clinical outcomes in a small 
sample size. 
-  In addition, it also highlights that EVH is likely to be cost effective, reduce post-
surgery costs and improves patients’ health-related quality of life. 
- Our data supports the use of endoscopic vein harvesting techniques as a routine 
care procedure for coronary artery bypass surgery in selected patients. 
- Practitioner experience is important in ensuring conduit quality as demonstrated by 
the difference between our pilot and randomised study data. 
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Introduction: 
Arterial conduits play a vital role in coronary artery bypass grafting (CABG) surgery due to 
their physical and functional properties. The Internal mammary arteries (IMA) are considered 
to be a gold standard conduit for bypass surgery due to its high patency rate and its long 
term survival rate1. Only 4% to 12% patients receive bilateral IMA in US and European 
countries2. The long saphenous vein (LSV) still remains the preferred conduit for multiple 
coronary artery bypass surgery due to its long length, and endoscopic vein harvesting (EVH) 
has demonstrated reduced postoperative morbidity and improved patient satisfaction 3, 4.  
Indeed, EVH is associated with markedly reduced scarring, diminished post-operative pain, 
greater patient mobility and reduced inflammation4. EVH also significantly reduces the 
likelihood of post-operative wound infections, potentially ameliorating the requirement for 
antibiotic usage5. Two EVH techniques exist: closed tunnel EVH (CT-EVH) and open tunnel 
EVH (OT-EVH), which differ on the basis of CO2 pressurisation and instrumentation.  
There is major debate regarding vein quality and long term clinical outcomes following EVH, 
largely due to the findings of a major study6, which revealed poorer outcomes with EVH. 
However, this raised questions about the use of different systems (CT-EVH was used for the 
majority of EVH cases in that study), case selection, operator experience 7 and other 
comorbidities 8. Previous studies 9-11 and systematic reviews 12, 13 have highlighted the need 
for an appropriately designed clinical trial to establish the effect of harvesting on vein 
integrity, downstream costs and clinical outcomes 14. This was reinforced by the International 
Society of Minimally Invasive Cardiac Surgery3 (ISMICS) and the National Institute for Health 
and Care Excellence 15, 16 (NICE). There are many studies that have compared EVH and 
OVH in relation to wound related complications and length of hospital stay, but still there is 
no study directly comparing three vein harvesting techniques on histological and clinical 
outcomes. 
  
5 
 
We designed a prospective single centre 3-armed randomised study comparing vein 
damage, clinical outcomes between two types of EVH (closed and open tunnel) and 
traditional open vein harvesting (OVH). A trial-based cost-effectiveness analysis was 
prospectively integrated within the study design to generate evidence on the cost-
effectiveness of the vein harvesting techniques. 
Methods: 
Study Design: 
The study was approved by the NRES Committee and conducted following the principles of 
the Declaration of Helsinki and Good Clinical Practice. This study was undertaken at the 
University Hospital of South Manchester NHS Foundation Trust and was overseen by an 
external steering committee, clinical trial unit, public patient involvement and safety 
monitoring board. The trial was registered on the IRAS trial registry prior to commencing 
patient recruitment. We also registered the trial on the International Standard Randomised 
Controlled Trial Registry (ISCTRN: 91485426) in line with EU regulation 536/2014 (the trial 
was submitted on 30th April 2014 and EU regulation 536/2014 was released on 27th May 
2014. The trial was fully registered on 18th September 2014). 
Informed written consented patients were prospectively recruited between November 2011 
and May 2015 from the cardiac waiting list (Figure 1). Patients who received single internal 
mammary artery and individual vein grafts (1-4) by on-pump bypass were included (full study 
protocol describing recruitment, clinical and health economics data collection, method of 
histological scoring and standard techniques included in supplemental material). Exclusion 
criteria included: emergency CABG, superficial LSV (less than ½ cm below the skin) or 
varicose LSV and/or small or thin legs (<7.5cm diameter at the lower calf), determined via by 
an ultrasound Sonasite™ scans 4. 
Patients were randomised to one of three groups with a 1:1:1 allocation ratio. Computerised 
simple block randomisation using random block sizes was performed by an independent 
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statistician. Patient allocation was revealed to the practitioner once the patient was 
anaesthetised. Data gathering researchers, the statistician, health economist and histologist 
were completely blinded to the study group assignments.  
Surgical techniques: 
OVH and EVH were performed as previously described4, 17. All veins were harvested by an 
experienced surgical practitioner (>250 cases for each EVH technique and >2000 open 
harvesting cases). However, the CABG surgery was performed by seven cardiac surgeons.  
Open vein harvesting - Control group: 
According to normal practice, a long incision was made from ankle to thigh depending upon 
the length of vein required for surgery. For the purpose of this study, the patients who 
required two lengths of vein had conduits harvested from just below the knee (approximately 
9cm). Patients who required three lengths of vein had the conduits harvested from 4cm 
above the medial malleolus bone. The vein side branches were ligated with 4-0 vicyrl ties 
and titanium clips on both sides4. 
Closed tunnel CO2 EVH: Intervention group 
The Maquet Vasoview Hemopro2® vein harvesting system which involves a pressurised 
CO2 tunnel for vein dissection was used. A 2-3cm incision was made just above or below the 
knee (approximately 9cm) depending upon the length of vein (1 or 2 or 3) required for 
surgery. The long saphenous vein was exposed and dissected using a West retractor and a 
Langenbeck retractor.  The CO2 insufflator was set to 3 litres/ min with 0mmHg pressure. 
Following completion of harvesting, patients received full heparinisation followed by cardio-
pulmonary bypass. CT-EVH patients received 5000 units of heparin before EVH to avoid 
intraluminal clot formation18. A 30mm, 0° endoscope with a sharp, clear dissecting cone on 
the tip was inserted through the skin incision. After 3cm of anterior dissection, the balloon 
was inflated to seal the incision port. A minimal amount (10ml) of trocar cuff air inflation was 
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used to reduce the trauma to the vein. The vein was dissected from the surrounding tissues 
anteriorly and posteriorly until reaching the femoral junction in the groin. The vein side 
branches were ligated with 4-0 vicyrl ties and titanium clips on both sides4. 
Open tunnel CO2 EVH: Intervention group 
The Sorin ClearGlide® vein harvesting system which involves non-pressurised CO2 tunnel 
for vein dissection was used.  A 2-3cm incision was made just above or below the knee 
(approximately 9cm) depending upon the number of vein lengths (1 or 2 or 3) required for 
surgery. Initially, the long saphenous vein was exposed and dissected using a West retractor 
and a Langenbeck retractor. A 30mm, 0° telescope with a ClearGlide dissecting retractor 
was introduced through the skin incision. The CO2 insufflator was set up at a continuous flow 
rate of 3 litres per minute and 0mmHg pressure. The vein was dissected from the 
surrounding tissue anteriorly and posteriorly until reaching the femoral junction in the groin. 
The vein side branches were ligated with 4-0 vicyrl ties and titanium clips on both sides. The 
small leg wound was closed in layers and a dressing and pressure bandage was applied4. 
 
Standardisation for all three group techniques: 
- The vein was harvested with surrounding fat and adventitial layers. The conduit was 
harvested 2 to 3 mm away from the main long saphenous vein. 
- All the branches were cut with at least 1cm length wherever possible.  
- The vein was inflated with heparinised arterial blood with 10mmHg inflation pressure 
using a pressure control syringe. 
- The cardioplegia vein perfusion flow pressure through the vein was standardised to 
70mmHg for all cases. 
- All patients requiring three lengths of vein had the conduits harvested from the ankle to 
the thigh. For patients who require one or two lengths, was harvested from just below or 
above the knee. 
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- The measurement of partial pressure of arterial carbon-dioxide (Paco2), Etco2 and also 
any changes to the ventilator settings during the vein harvesting procedure was 
monitored and recorded for this study. 
Histological assessment: 
2700 vein samples were numerically coded to ensure laboratory blinding. Surgically 
undistended vein samples (n=900) were obtained proximally at the port of entry and coded 
H1. Distal vein samples (n=900) obtained after 10mmHg heparinised blood flush to check for 
leakages were coded H3. Following vein grafting, a random sample was obtained from the 
remaining conduit, and coded H2 (n=900). Therefore H2 samples underwent all distension 
and manipulation as required for surgical preparation. As such, these samples provide the 
best possible representation of the entire vein at different stages following harvesting that 
could be achieved given the logistics of the operation. These H2 samples were randomly 
given by the cardiac surgeons who weren’t told about the type of vein harvesting procedure 
to avoid any bias in relation to which segment given for research purposes. 
A computerised immunohistochemistry protocol was used to stain CD34 (a validated 
endothelial marker)19 of each vein sample from batch 1 (n=900; H1, H2, H3). A validated 
scoring system was used to grade endothelial integrity20 (0-100% intact (positive staining), 
supplemental figure 1). The second batch of 900 vein samples was stained with Picrosirius 
red muscular and collagen stain (80-picrosirius red; Sigma-Aldrich Ltd, Dorset, UK) to 
assess structural damage in the muscular layers. We refined/ modified the existing scoring 
system (full detailed scoring in study Protocol attached as a supplemental file) for simplicity, 
which was used to grade muscular hypertrophy (the term hypertrophy in this study means 
acute swelling rather than chronic process of the muscle injury), detachment, muscle 
migration on a scale of 0-3 (normal, mild, moderate, severe, supplemental figure 2). The final 
batch of 900 vein samples was stained with Haematoxylin & Eosin (H&E) to assess 
endothelial stretching and detachment. Endothelial damage was graded on a scale of 0-3 
(normal, mild, moderate and severe)19. 
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All slides were scanned using a Pannoramic 250™ slide scanning system. All histology 
images were scored by 5 independent assessors and validated by a consultant 
histopathologist. 
Study outcome measures: 
The primary outcome measure was severity of histological damage to the vein conduits. The 
association between histological damage and pre-defined clinical outcomes was then 
assessed. Complete demographics, intraoperative details, incidence of wound infection and 
General Practitioner/district nurse visits were recorded.  
The secondary end-points included incidence of Major Adverse Cardiac Events (MACE), use 
of healthcare resources and impact on health status. MACE was defined as repeat angina, 
breathlessness, myocardial ischemia/infarction, re-intervention, stroke and death. MACE 
were determined by telephone interviews, clinic letters, general practitioner and coroner 
reports at 3 month intervals until 12 months and then at 18, 24, 36 and 48 months. Only 
symptomatic MACE patients underwent cardiac MRI scans and angiograms were reviewed 
by an independent cardiologist and a cardiac surgeon.   
An NHS and social services perspective was used for the scope of the collection of 
healthcare resources. All healthcare resources associated with treatment and follow-up care 
was recorded prospectively. For a full list of healthcare utilisation data collected 
(supplemental table 1) and unit costs which were sourced from the procurement and finance 
department at the hospital and national databases where relevant for follow-up care20, 21. The 
vein harvesting procedure was micro-costed, with the fixed cost of the vein harvesting 
equipment fully absorbed in each arm of the trial. The length of time within theatre required 
for vein harvesting was recorded and costed.  
The impact on each individual’s health status was assessed at 3 and 12 months using EQ-
5D-3L which has five domains (Mobility, Self-Care, Usual Activities, Pain and Discomfort, 
Anxiety and Depression) and three levels within each domain (‘no problems’, ‘some 
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problems’, ‘severe problems’). Using a published national tariff 22, each completed EQ-5D-3L  
questionnaire for each patient was converted into an index measure of health-related quality 
of life (HRQoL) on a scale of 1 equal to full health and 0 equal to death. Health states with a 
HRQoL less than death were also included. Patients who died had a HRQoL of 0 inputted.    
QALYs were calculated using the area under the curve method using the trapezoid rule and 
linear interpolation between the measures of HRQoL at the two time-points. As a one year 
time horizon was chosen no discounting was applied to the cost or QALY data. 
Power calculation: 
To generate an accurate power calculation we undertook a non-randomised pilot study 
comparing the impact of the different vein harvesting techniques on endothelial integrity 
using 140 patients. Based on this pilot data we calculated that 91 patients in each of the 
three groups (OVH, CT-EVH and OT-EVH), i.e. 273 in total, would provide 80% power to 
detect differences in the percentage with zero endothelial integrity of 20% or more (for 
example 20% vs. 40%) in this study. This calculation was based on a comparison of two 
groups using a simple chi-square test, with continuity correction at the 5% significance level. 
A recruitment strategy requiring a total of 300 patients with a 10% drop out rate was used. 
Clinical outcomes in our pilot study demonstrated that 19% of closed tunnel CO2 patients 
experienced MACE compared to 13% of open tunnel CO2 patients (ie only a 6% difference 
in incidence).  
Statistical analysis: 
All demographics were summarised as frequencies/percentages for categorical variables 
and means/median with standard deviation/interquartile range as appropriate for continuous 
variables. Endothelial integrity as determined by CD34 expression was presented as median 
percentage integrity and other histological outcomes were presented as median scores and 
analysed using the Kruskal-Wallis test. Composite and individual MACE events were 
analysed at each time point using the chi-square test. All tests were performed as two-tailed 
analyses and p-values <0.05 were considered significant. 
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The chi-squared test was used to compare how patients completed the EQ-5D-3L profile 
across the arms of the trial with p-values <0.05 considered to be significant. Incremental 
costs, incremental QALYs and incremental net benefit at a decision-maker’s threshold of 
£20,000 per QALY were calculated using regression analysis controlling for baseline disease 
severity measured by EQ-5D and the Canadian Cardiovascular Society grading score. For 
both costs and QALYs, different generalised linear models (GLM) were tested to assess for 
fit to the data. The appropriate family for the GLMs was assessed using the Park test. The 
appropriate link for the GLMs was assessed using the Pearson correlation test, the Pregibon 
link test and the Modified Hosmer & Lemeshow test 23.  
For all regression models, a GLM model with an identity link and Gaussian family, equivalent 
to ordinary least squares, were found to be the best specified and was used for the analysis. 
Statistical uncertainty was considered by using a non-parametric bootstrap method24 
accommodating for the correlation between costs and QALYs and 1000 bootstrap replicates 
for each estimate was generated. Probabilities of cost-effectiveness were calculated by 
measuring the proportion of bootstrap replicates with a positive net-benefit for a given cost-
effectiveness threshold. A complete set of data was available for HRQoL and healthcare 
resource use and so no form of imputation was used. 
Pilot work:  
A pilot study was designed to determine study sample size for the primary end-point and 
demonstrated that OT-EVH (n=70) better preserved conduit endothelium compared to CT-
EVH (n=70) (median 65.0% vs. 11.4%, p<0.001, supplemental figure 3). However, no 
significant differences were observed between groups for MACE events including repeat 
angina (p=0.62), breathlessness (p=0.80), re-intervention (p=1.00), myocardial 
infarction/ischaemia (p=1.00) or mortality (p=0.44) up to 5 years post-surgery (supplemental 
table 2).  
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Results: 
Demographics: 
398 patients were enrolled but 24.6% (98 patients) were excluded from the study based on 
predefined exclusion criteria. 98 patients were excluded before the randomisation of the 
patient allocation numbers, so they were not allocated into any specific trial groups (Figure 
1). This method was used to avoid major drop out from the study. Our previous patient 
recruitment for the clinical trials indicated that patients change their participation in the trial or 
surgery schedule changes to accommodate emergency and urgent in patient referrals. 301 
patients underwent randomisation and there were no clinically relevant differences between 
groups (table 1). However, one patient in OVH group was excluded after surgery because 
tissue samples not collected. A higher body mass index, more left main stem and current 
smokers were observed in the CT-EVH group. Intraoperative variables were recorded, 
including surgical timings and number of veins required (supplemental table 3). 
Primary histological outcomes:  
Endothelial integrity: CD34  
Endothelial integrity was better preserved in the OVH group in proximal samples compared 
to endoscopic techniques (median percentage integrity [IQR]: 91.50 [12.50] vs. 91.63 [10.56] 
vs. 95.75 [6.69] for CT-EVH vs. OT-EVH vs. OVH respectively, p<0.001, figure 2). Random 
samples from the OVH group displayed greatest endothelial integrity compared to the other 
groups (85.25 [21.13] vs. 87.50 [21.00] vs. 92.71 [13.13] for CT-EVH vs. OT-EVH vs. OVH 
respectively, p<0.001, figure 2). However, no statistical difference was observed in distal 
samples (92.25 [10.88] vs. 91.75 [13.81] vs. 95.38 [9.25] for CT-EVH vs. OT-EVH vs. OVH 
respectively, p=0.07, figure 2). 
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Muscular morphology: Picrosirius red and H&E 
Endothelial stretching of proximal vein samples was greatest in OT-EVH group (66.0%), 
followed by CT-EVH (61.0%), with least stretching in OVH (46.0%, p=0.01). No differences 
in endothelial stretching were observed between groups in distal (53.5% vs. 51.5% vs. 
41.0% for OT-EVH, OVH and CT-EVH respectively, p=0.16) or random (37.4% vs. 31.3% 
vs. 36.7% for OT-EVH, OVH and CT-EVH respectively, p=0.62) samples. The level of 
endothelial detachment was consistent between groups in proximal (2% vs. 3% vs. 2% for 
OT-EVH, OVH and CT-EVH, p=0.25), distal (4% vs. 1% vs. 6% for OT-EVH, OVH and CT-
EVH, p=0.63) and random (5% vs. 2% vs. 5% for OT-EVH, OVH and CT-EVH, p=0.47) 
samples.  
The circular muscle layer displayed greatest hypertrophy in proximal samples from the OT-
EVH group (65.6%) followed by CT-EVH (45.0%) and OVH (14.3%, p<0.001). A similar 
pattern was observed in distal (46.3% vs. 24.2% vs. 38.8% for OT-EVH, OVH and CT-EVH, 
p<0.001) and random (35.4% vs. 14.1% vs. 31.3% for OT-EVH, OVH and CT-EVH, p=0.01) 
samples. The longitudinal muscle layer displayed greatest hypertrophy in proximal samples 
from the OT-EVH group (56.2%) compared to OVH (5.1%) and CT-EVH groups (23.0%, 
p<0.001). Greatest longitudinal hypertrophy was observed in distal samples from the OT-
EVH group (26.3%), followed by CT-EVH (8.2%) and OVH (1.0%, p<0.001). Moreover, OT-
EVH displayed greatest longitudinal hypertrophy in random samples (13.5%), compared to 
OVH (3.0%) and CT-EVH (1.0%, p=0.001).  
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Secondary outcomes – clinical events and cost effectiveness: 
Composite and individual MACE scores were analysed in this study to avoid any varying 
definitions of composite outcomes. Kip et al15 suggested that authors should focus 
separately on safety and effectiveness outcomes.  
Composite MACE scores: 
The incidence of composite MACE events were analysed at each time point up to 48 
months. No significant differences were observed between groups at any point (Figure 3a 
and supplemental table 4). Endothelial integrity did not differ between patients with or 
without MACE at 24 months (with n=299) in proximal samples (median percentage integrity 
[IQR]: 93.58 [11.42] vs. 92.33 [7.54] for MACE-free and MACE-affected respectively, 
p=0.48), distal samples (93.08 [11.81] vs. 96.25 [11.50], p=0.26) or random samples (88.75 
[18.56] vs. 87.25 [23.92], p=0.64). 
A statistically significant body mass index (BMI), left main stem and current smokers were 
observed in CT-EVH group. A Cox proportional hazard model was considered. After 
adjusting for these variables, it does not appear to be a statistically significant relationship 
between the groups and time to first MACE event (p=0.61) (table 2). However, these results 
should be interpreted cautiously due to small number of MACE events occurred in this study. 
Individual MACE events: 
The secondary outcomes demonstrated that no significant difference in MACE events was 
observed between groups, other than slightly higher mortality at 3 and 6 months (p=0.05 and 
p=0.03 respectively), in the OT-EVH group (Figure 3b) although these deaths were not 
MACE related mortalities. Atrial fibrillation occurred in 9 patients and vein graft blockage was 
noted in 6 patients, although incidence was not influenced by group (p=0.69 and p=0.42 
respectively, table 3). No statistically significant difference in MACE outcomes at each time 
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point up to 48 months was observed between operating surgeons (p=0.76, p=0.78, p=0.26, 
p=0.23 and p=0.21 respectively).  
Cost effectiveness analyses: 
Vein harvesting costs for both the endoscopic approaches were more expensive than the 
use of traditional OVH. The use of CT-EVH increased costs by £1180 (p<0.001) whilst OT-
EVH increased costs by £981 (p<0.001) per patient over OVH. This increase in cost was 
due to one-off payments for the visual equipment needed to conduct the endoscopic 
extraction as well as an increase in variables costs required for each operation, such as the 
need for additional disposable tubing and camera drapes. However, both endoscopic 
approaches led to lower downstream costs associated with follow-up care.  
There was a reduction in post-operation costs for GP visits, district nurse visits and hospital 
stays (p<0.001). There was also a reduction in the cost for postoperative antibiotics usage, 
other medications, as well as the cost associated with ‘wound infection packages’ which 
includes readmission to the hospital, re-theatre costs for additional procedures and vac 
therapy. Consequently, for follow-up care, CT-EVH led to a mean reduction in downstream 
costs of £814 (p=0.002) per person versus OVH whilst OT-EVH led to a mean reduction of 
£598 (p=0.03). Overall, when combining the vein harvesting cost and the downstream costs, 
both EVH methods led to net cost increases over OVH, by £274 (p=0.34) for CT-EVH and 
£436 (p=0.16) for OT-EVH per patient although neither were statistically significant.  
Both endoscopic approaches led to a marked improvement in health-related quality of life 
compared to the use of OVH. Figure 4a and Figure 4b shows how patients completed the 
EQ-5D-3L at 3 and 12-months respectively. At 3-months, in the domains for Mobility, Self-
Care, Usual Activities and Pain and Discomfort, patients were more likely to report having 
some problems in the OVH arm compared to the endoscopic arms (p<0.001). At 12-months, 
patients were still more likely to report as having some problems for the domains Self-Care 
(p=0.02), Usual Activities (p=0.01) and Pain and Discomfort (p=0.004) but there was no 
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significant effect for Mobility (p=0.051). For the domain Anxiety and Depression there was no 
difference between the arms at either 3-months (p=0.30) or 12-months (p=0.32).  
Supplemental figure 4 illustrates the impact on the EQ-5D-3L index after the EQ-5D-3L 
profiles have been weighted by the UK national tariff. The biggest difference in HRQoL 
occurs at 3-months where patients in both endoscopic arms have higher HRQoL compared 
to OVH (p<0.001). At 12-months there is an improvement in HRQoL across all arms and 
some narrowing between the harvesting methods. At 12-months both endoscopic 
approaches have higher mean values than OVH which is statistically significant for CT-EVH 
versus OVH (p=0.004) although insignificant for OT-EVH (p=0.128). After calculating the 
area under the curves, there was an increase in QALYs of 0.11 per patient (p=0.001) for the 
CT-EVH arm versus OVH whilst OT-EVH had an increase in QALYs of 0.07 per patient 
(p<0.003) versus OVH.  
When considering the costs and health benefits together to assess cost-effectiveness, CT-
EVH had an incremental net-benefit per patient of £1927 versus OVH and a 75% likelihood 
of being cost-effective. This probability for cost-effectiveness is based on a decision-maker 
being willing to spend an additional £20,000 for every additional QALY generated, called the 
cost-effectiveness threshold. OT-EVH had an incremental net-benefit per patient of £950 
versus OVH and a 19% likelihood of being cost-effective at a threshold of £20,000 per 
QALY. OVH had a low likelihood (6%) of being cost-effective (figure 5a & b) 
Safety and clinical relevance: 
At 24 months, composite MACE events were observed in 33 patients; (OVH (10/100), CT-
EVH (11/100) and OT-EVH (12/100)). 289 patients survived, with non-cardiovascular 
associated mortality in 11 patients due to ischemic bowel, pneumonia, liver failure and 
cancer. No mortality associated with cardiovascular events was observed. MACE repeat 
angina events (table 3) were observed in 16 patients during the study period. Follow-up MRI 
and angiogram evaluation in symptomatic patients concluded that angina was caused by 
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native artery disease progression (4/16), vein graft insertional site stenosis (4/16), vein graft 
blocked (2/16), previous patent stent blocked (4/16) and left internal mammary artery 
insertional site stenosis (5/16). The vein conduits could not be grafted at the time of 
operation due to calcified/small coronaries in 3/16 patients. Multiple causes were observed 
in 5 patients.  
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Discussion: 
This is the first study with direct head to head comparison of two EVH techniques with 
traditional OVH in relation to histological vein integrity and clinical outcomes. EVH has a 
number of important benefits, and is associated with markedly improved post-operative 
patient satisfaction due to significantly less scarring, contributing to reduced pain and 
improved patient mobility compared to OVH. The smaller scar is also less likely to become 
infected, therefore necessitating less post-operative follow-up care. If graft patency can be 
maintained with EVH, then this would be a preferred option to OVH in suitable patients.  
We report there was some vein injury in EVH compared to OVH (with loss of endothelial 
integrity, increased endothelial stretching, and muscle hypertrophy most severe in OT-EVH 
compared to CT-EVH and OVH). This study was powered for primary outcome using our 
pilot work results to see percentage of patients with zero endothelial injury but we have not 
observed any conduits with zero endothelial integrity any of the groups. Severe stretching 
and muscle migration has been associated with graft occlusion25, 26, yet only a small 
proportion of vein samples had severe intimal stretching in the OT-EVH group, and our sub-
analysis could not detect an association with MACE events. 
In 2009, a major non-randomised study concluded that EVH had higher rates of vein graft 
failure and mortality within 12-18 months post-surgery6. However, secondary outcomes from 
our randomised study demonstrate no statistically significant difference in composite or 
individual MACE scores with EVH, albeit with a low sample size precluding firm conclusions 
from being made. Furthermore, MACE scores did not correlate with vessel injury. This 
corroborates findings from previous studies describing positive clinical outcomes3, 12, 14 with 
both EVH and OVH and provides insight into the risk factors for MACE.  
Repeat angina and re-intervention in patients in this study were mainly due to grafting 
technique and technical error27, 28, poor target artery quality11, progression of native coronary 
artery diseases8 and previous stent blockage post CABG surgery. Whilst the importance of 
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grafting technique is highlighted by our findings, we did not observe significant intra-operator 
effects on MACE outcomes.  
According to the ISMICS consensus statement 3, studies comparing OVH versus EVH have 
focused only on the cost of wound complications29, readmissions and hospital stay30 but no 
analysis of incremental cost-effectiveness has been conducted. Our study highlights that 
both EVH techniques led to modest net increases in cost versus OVH during surgery. 
However, both EVH techniques substantially reduced post-surgery costs and improved 
patients’ health-related quality of life leading to relatively large gains in QALYs when 
compared with other technologies31. The use of CT-EVH was associated with lower costs 
and better outcomes when compared with OT-EVH. Therefore CT-EVH may represent the 
optimal cost-effective technique for vein harvesting. 
Limitations: 
This study was designed to utilise a single experienced practitioner from one centre to 
determine the impact of harvesting techniques. Different operators will inevitably introduce 
variability in surgical skills which could confound a true comparison. The practitioner had 
experience of >2000 OVH cases but only 250 EVH cases and this may have implications on 
surgical timings, quality of the OVH vein conduit and post-operative complications, which 
need to be taken into consideration when interpreting the data. Also, not all study 
participants underwent routine angiogram or cardiac MRI scans due to ethical, financial 
restrictions within the NHS and risks involved due to patients’ age. The current study is 
underpowered to detect small differences in clinical outcomes as >1000 patients would be 
required in each arm, which would not be possible for a single centre study. However, this 
study was designed with graft histology as the primary outcome as this has been 
understudied to date and is an important area. For these purposes, a single centre, single 
practitioner model was most appropriate. The principal reason for using a sole operator for 
this study is to minimise the incidence of practitioner skill error. Also, we performed 
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comparisons of MACE incidence at multiple time points, which could increase the likelihood 
of type 1 error and obtaining statistically significant results by chance. However, we did not 
detect statistical differences in individual MACE events at any time point, and so type 1 error 
did not alter our conclusions. 
Conclusion:  
Our study demonstrated that endoscopic vein harvesting does cause minimal damage to the 
layers of the vein.  However, the small sample size in this study makes it difficult to conclude 
what impact this injury has on clinical outcomes with large sample size. Endoscopic vein 
harvesting also provides better health-related quality of life, QALYs and is more cost- 
effective than open vein harvesting post CABG surgery. Therefore endoscopic vein 
harvesting can be utilised for vein harvesting safely with appropriate patient selection, 
equipment and better structured training in future practitioners. This study provides a base 
for future multicentre studies and also clarifies that histological damage is minimal when 
practitioners are experienced. 
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Figure Legends: 
Figure 1: Consort diagram demonstrates the detailed enrolment, treatment and follow up of the VICO 
trial patients.  
Figure 2: This figure illustrates the median percentage endothelial integrity on proximal (H1), random 
(H2) and distal (H3) vein samples between CT-EVH, OT-EVH and OVH groups.  
igure 3: This Kaplan-Meier figure illustrates the time to MACE events (a) and cumulative survival (b) 
at different time points until 48 months. There does not appear to be a statistically significant 
difference between the groups in their MACE event times (log-rank test p=0.56) nor their mortality and 
survival. 
Figure 4: This figure shows how patients completed the EQ-5D-3L (% selecting level) for each arm of 
the trial at 3-months (a) and 12 months (b).   
Figure 5: A) Cost-effectiveness plane showing incremental costs and QALYs of CT-EVH and OT-
EVH versus OVH. Bootstrap replicates (n=2000) show the uncertainty with the larger points showing 
the point estimates. A cost-effectiveness threshold of £20,000 per QALY is presented. For a 
technology in the North-East quadrant, a cost-effective technology is one where the point estimate 
and a high proportion of bootstrap replicates falls below (South-East) the threshold line. B) Cost-
effectiveness acceptability curve for OVH, CT-EVH and OT-EVH which is plotted by calculating the 
proportion of bootstrap replicates falling below the cost-effectiveness threshold line as the threshold is 
varied. The typical threshold used by NICE is taken to be between £20,000-£30,000 per QALY. 
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Table 1:  Demographic data including pre-operative co-morbidities, risk factors and cardiac history. 
Demographic variables 
Group p-value 
OT-EVH (n=100) OVH (n=100) CT-EVH (n=100)  
Age (years) 66.92±10.08 65.96±9.34 64.06±10.20 0.12 
Sex (M/F) 82/18 (82.0%/18.0%) 79/21 (79.0%/21.0%) 79/21 (79.0%/21.0%) 0.83 
Body Mass Index (BMI) 27.77 [6.41] 27.93 [5.45] 28.78 [6.54] 0.04 
Surgery:                    Elective                                                         
46 (46.0%) 49 (49.0%) 41 (41.0%) 
 
0.52 
                                     Urgent 
54 (54.0%) 51 (51.0%) 59 (59.0%) 
Diabetes:              Diet controlled                                  8 (8.0%) 6 (6.0%) 4 (4.0%) 0.49 
Tablet controlled 21 (21.0%) 27 (27.0%) 22 (22.0%) 0.56 
Insulin controlled 8 (8.0%) 11 (11.0%) 4 (4.0%) 0.18 
CCS* score                                 I                                                                              17 (17.0%) 17 (17.0%) 12 (12.0%)  
 
0.69 
II 25 (25.0%) 29 (29.0%) 33 (33.0%) 
III 45 (45.0%) 45 (45.0%) 46 (46.0%) 
IV 13 (13.0%) 9 (9.0%) 9 (9.0%) 
New York Heart Association:   I           27 (27.0%) 32 (32.0%) 40 (40.0%)  
 
0.05 
II 45 (45.0%) 35 (35.0%) 26 (26.0%) 
III 26 (26.0%) 25 (25.0%) 29 (29.0%) 
IV 2 (2.0%) 8 (8.0%) 5 (5.0%) 
STEMI* 18 (18.0%) 19 (19.0%) 29 (29.0%) 0.12 
NSTEMI* 42 (42.0%) 48 (48.0%) 44 (44.0%) 0.69 
Previous PTCA* 16 (16.0%) 12 (12.0%) 20 (20.0%) 0.30 
Previous MI 52 (52.0%) 43 (43.0%) 54 (54.0%) 0.25 
Multivessel disease 82 (82.0%) 81 (81.0%) 86 (86.0%) 0.61 
Left main stem  25 (25.0%) 25 (25.0%) 40 (40.0%) 0.03 
Hypertension 87 (87.0%) 83 (83.0%) 88 (88.0%) 0.56 
Smoking:              Never smoked 32 (32.0%) 33 (33.0%) 23 (23.0%)  
0.03 Previous smoker 52 (52.0%) 54 (54.0%) 47 (47.0%) 
Current smoker 16 (16.0%) 13 (13.0%) 30 (30.0%) 
Hypercholesterolemia 96 (96.0%) 90 (90.0%) 92 (92.0%) 0.25 
Peripheral vascular disease 19 (19.0%) 20 (20.0%) 21 (21.0%) 0.94 
Left Ventricular ejection fraction                  
                                           >50% 
 
74 (74.0%) 
 
74 (74.0%) 
 
72 (72.0%) 
 
 
0.88 30-50% 21 (21.0%) 18 (18.0%) 22 (22.0%) 
<30% 5 (5.0%) 8 (8.0%) 6 (6.0%) 
Categorical variables are expressed as number (%) and assessed by the χ
2 
test. Continuous variables are expressed as either 
mean±standard deviation (parametric data) or median [interquartile range] (non-parametric data) and analysed by ANOVA or 
Independent samples Kruskal-Wallis test respectively.  * STEMI- ST elevated myocardial infarction, NSTEMI – Non ST 
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elevated myocardial infarction, PTCA – Percutaneous coronary angioplasty and CCS score – Canadian Cardiovascular Society 
score. 
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Table 2: Cox PH model for MACE events. 
Unadjusted Cox PH model for MACE events 
 
Variable: Groups Hazards ratio (95% CI) p-value 
CT-EVH 
OT-EVH 
OVH 
1 (-) 
1.30 (0.62-2.70) 
0.86 (0.39-1.93) 
0.56 
 
 
 
Adjusted Cox PH model for MACE events 
 
Variable: Groups Hazards ratio (95% CI) p-value 
CT-EVH 
OT-EVH 
OVH 
1 (-) 
1.24 (0.58-2.66) 
0.85 (0.37-1.95) 
0.61 
 
 
BMI (per unit increase) 0.96 (0.89-1.04) 0.30 
Left main stem 
No 
Yes 
 
1 (-) 
2.00 (1.05-3.80) 
0.034 
 
 
Smoking 
Never smoked 
Previous smoker 
Current smoker 
 
1 (-) 
1.29 (0.61-2.72) 
1.19 (0.46-3.03) 
0.80 
 
 
 
New York Heart Association 
I 
II or more 
 
1 (-) 
4.91 (1.74-13.86) 
0.003 
 
 
 
After adjusting for BMI, left main stem, smoking status and New York Heart Association grade – the variables that appear to be 
unbalanced between the randomisation groups – there does not appear to be a statistically significant relationship between 
group and time to first MACE event (p=0.61). The regression parameters and hazard ratios appear similar for the group 
variable in the unadjusted and the adjusted Cox PH analysis, suggesting the possible imbalances in the 4 other variables 
between the randomisation groups do not impact its relationship with time to first MACE event. These results should be 
interpreted cautiously due to the number of MACE events (totalling 33) and the number of parameters estimated in the adjusted 
Cox PH model, which was seven. 
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Table 3: The incidence of post-operative complications and investigations 
 
Post-operative complications and investigations carried out for the participants post CABG surgery during the follow up period 
are listed from the day of surgery until 48 months.  In addition to the incidences, the detailed causes of MACE events have 
been listed. *represents that the same patient had multiple MACE causes.  
 
 
 
Variable CT-EVH OT-EVH OVH p-value 
Chest wound numbness 57 (57.0%) 39 (40.2%) 52 (52.0%) 0.05 
Chest wound tenderness 49 (49.0%) 34 (35.1%) 42 (42.4%) 0.14 
Leg wound numbness 3 (3.0%) 10 (10.3%) 52 (52.5%) <0.001 
Leg wound tenderness 3 (3.0%) 7 (7.2%) 36 (36.4%) <0.001 
Arrhythmias 2 (2.0%) 3 (3.0%) 2 (2.1%) 0.87 
Atrial fibrillation 2 (2.0%) 3 (3.0%) 4 (4.1%) 0.69 
Ventricular fibrillation/tachycardia 0 (0.0%) 0 (0.0%) 0 (0.0%) --- 
Pacemaker fitted 2 (2.0%) 2 (2.0%) 1 (1.0%) 0.83 
MRI performed 2 (2.0%) 6 (6.0%) 3 (3.1%) 0.30 
Angiography performed 2 (2.0%) 5 (5.2%) 5 (5.2%) 0.43 
Total MACE  4 (4.0%) 6 (6.0%) 6 (6.0%) 0.77 
Cause of MACE events. 
Vein not used due to small 
native coronary artery 
2* 1 0 
--- 
Native artery disease 1 1* 2 
Previous stent blocked 2* 1 1 
LIMA blocked 1* 2* 2 
Vein graft insertional stenosis 0 2* 2 
Vein graft blockage 0 2* 0 
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Supplemental material: 
Supplemental table 1: Resource use and unit costs in the analysis 
Resource-use 
item 
Cost type  Fixed 
cost total 
Unit cost* Sourc
e Year 
Source Years need 
inflating 
Unit cost 
Vein Extraction        
West retractor 
(one off payment) 
Fixed  £                                 
78.80  
£                       
2.75  
2014 Finance  
department 
1  £                 
2.78  
Sterilisation 1 Variable   £                         
2.00  
2014 Finance  1  £                 
2.02  
Langebeck 
retractor 
small(one off 
payment) 
Fixed  £                                 
46.52  
£                         
3.32  
2014 Finance  1  £                 
3.36  
Sterilisation 2 Variable   £                         
2.00  
2014 Finance  1  £                 
2.02  
Vein harvesting 
set (cut down)one 
off payment 
Fixed  £                               
293.70  
£                         
6.59  
2014 Finance  1  £                 
6.66  
Sterilisation 3 Variable    £                       
12.00  
2014 Finance  1  £               
12.13  
Disposables (in theatres and ward, 
community) 
  
   -          
Leg vaccum drain 
size 10 
Variable   £                         
7.52  
2013 Procurement 2  £                 
7.67  
Dressings large 
each 
Variable   £                         
1.15  
2013 Procurement 2  £                 
1.17  
Dressings small 
each 
Variable   £                         
0.66  
2013 Procurement 2  £                 
0.67  
Bandages 6" each Variable    £                         
0.84  
2013 Procurement 2  £                 
0.86  
Sutures               
2/0vicryl each Variable   £                         
3.45  
2013 Procurement 2  £                 
3.52  
3/0monocryl Variable   £                         
3.50  
2013 Procurement 2  £                 
3.57  
Vicryl ties4/0 each Variable   £                         
4.22  
2013 Procurement 2  £                 
4.31  
Drain stitch each Variable   £                         
1.57  
2013 Procurement 2  £                 
1.60  
Swabs(5 pieces 
per pack) 
Variable   £                         
1.12  
2013 Procurement 2  £                 
1.14  
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Red ligaclips pack 
4 
Variable   £                       
27.60  
2013 Procurement 2  £               
28.16  
Blue ligaclips 
pack 4 
Variable   £                       
29.20  
2013 Procurement 2  £               
29.79  
Theatre time Variable   £                       
15.12  
2013 Procurement 2  £               
15.43  
Total leg 
operation surgery 
timings 
       
EVH- disposable 
kit 
Variable   £                     
550.00  
2013 Procurement 2  £            
561.10  
Camera drapes  Variable   £                     
190.58  
2013 Procurement 2  £            
194.43  
Lens cleaner  Variable   £                       
79.59  
2013 Procurement 2  £               
81.20  
CO2 tubing  Variable   £                     
173.13  
2013 Procurement 2  £            
176.63  
Light lead one off 
payment 
Fixed  £                               
295.00  
£                         
0.06  
2013 Procurement 2  £                 
0.06  
Telescope one off 
payment 
Fixed  £                           
2,571.00  
£                         
0.47  
2013 Procurement 2  £                 
0.48  
Hemoprobe cable 
one off payment  
Fixed  £                               
220.00  
£                         
0.04  
2013 Procurement 2  £                 
0.04  
TV, camera 
monitor stack 
machine one off 
payment for 10 
years 
Fixed  £                         
35,725.00  
£                       
19.27  
2013 Procurement 2  £               
19.66  
Power supply 
Haemoprobe one 
off payment 
Fixed  £                           
4,025.00  
£                         
2.17  
2013 Procurement 2  £                 
2.22  
Follow-up care               
ECG per visit Variable   £                       
62.00  
2013 Finance  2  £               
63.25  
ECHO per visit Variable   £                     
111.00  
2013 Finance  2  £            
113.24  
Cardiac MRI scan 
per visit 
Variable   £                     
534.00  
2013 Finance  2  £            
544.78  
Angiogram visit 
urgent 
Variable   £                 
3,213.87  
2013 Finance  2  £         
3,278.75  
Angiogram day 
case 
Variable   £                 
1,367.36  
2013 Finance  2  £         
1,394.96  
PTCA elective Variable   £                 
3,045.28  
2013 Finance  2  £         
3,106.76  
PTCA day case Variable   £                 2013 Finance  2  £         
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2,978.67  3,038.80  
GP visit Variable   £                       
53.00  
2015 PSSRU 0  £               
53.00  
District nurse 
home visits 
Variable   £                       
24.00  
2015 PSSRU 0  £               
24.00  
Antibiotic Variable   £                         
7.20  
2015 Pharmacy 0  £                 
7.20  
Cardiology follow-
up 
Variable   £                       
97.78  
2013 Finance  2  £               
99.75  
Cardiac surgeon 
follow-up 
Variable   £                     
189.69  
2013 Finance  2  £            
193.52  
Pacemaker stay 
and cost of the 
device etc) 
Variable   £                 
1,495.00  
2013 Finance  2  £         
1,525.18  
wound infection 
full 
package(includes 
readmission, itu, 
ward, retheatre 
procedure, vac 
therapy) 
Variable   £                 
7,250.00  
2013 Finance  2  £         
7,396.36  
Hospital stay  Variable   £                     
250.00  
2013 Finance  2  £            
255.05  
Medications  Variable   £                 
1,000.00  
2015 Pharmacy 0  £         
1,000.00  
Surgical 
intervention  
Variable   £                 
6,000.00  
2015 Finance  0  £         
6,000.00  
 
